Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Human Immunodeficiency Virus (HIV)-1 Therapeutics market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Human Immunodeficiency Virus (HIV)-1 Therapeuticsmarket, defines the market attractiveness level of Human Immunodeficiency Virus (HIV)-1 Therapeutics market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Human Immunodeficiency Virus (HIV)-1 Therapeutics industry, describes the types of Human Immunodeficiency Virus (HIV)-1 Therapeutics market, the applications of major players and the market size, and deeply analyzes the current situation of the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market and the development prospects and opportunities of Human Immunodeficiency Virus (HIV)-1 Therapeutics industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market in Chapter 13.
By Player:
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (US)
Genentech Inc (US)
Cipla Inc (India)
Merck & Co Inc (US)
AbbVie Inc(US)
By Type:
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
By End-User:
Hospitals
Clinics
Labs
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis and Outlook to 2022
-
7.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
7.2 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
7.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
7.4 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
7.5 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
7.6 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
-
7.7 South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption (2017-2022)
8 Region and Country-wise Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis and Outlook to 2028
-
8.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
8.2 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
8.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
8.4 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
8.5 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
8.6 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
-
8.7 South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast (2022-2028)
9 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Outlook by Types and Applications to 2022
-
9.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Entry and Fusion Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Protease Inhibitors (PIs) Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Integrase Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Coreceptor Antagonists Consumption and Growth Rate (2017-2022)
-
9.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Labs Consumption and Growth Rate (2017-2022)
10 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Outlook by Types and Applications to 2028
-
10.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Entry and Fusion Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Protease Inhibitors (PIs) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.5 Global Integrase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.1.6 Global Coreceptor Antagonists Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Labs Consumption Forecast and Growth Rate (2022-2028)
11 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Import and Export Analysis (Top 5 Countries)
-
11.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Competitive Analysis
-
14.1 Boehringer Ingelheim GmbH (Germany)
-
14.1.1 Boehringer Ingelheim GmbH (Germany) Company Details
-
14.1.2 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Service
-
14.2 Bristol-Myers Squibb Company (US)
-
14.2.1 Bristol-Myers Squibb Company (US) Company Details
-
14.2.2 Bristol-Myers Squibb Company (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Bristol-Myers Squibb Company (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Service
-
14.3 Genentech Inc (US)
-
14.3.1 Genentech Inc (US) Company Details
-
14.3.2 Genentech Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Genentech Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Service
-
14.4 Cipla Inc (India)
-
14.4.1 Cipla Inc (India) Company Details
-
14.4.2 Cipla Inc (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Cipla Inc (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Service
-
14.5 Merck & Co Inc (US)
-
14.5.1 Merck & Co Inc (US) Company Details
-
14.5.2 Merck & Co Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Merck & Co Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Service
-
14.6 AbbVie Inc(US)
-
14.6.1 AbbVie Inc(US) Company Details
-
14.6.2 AbbVie Inc(US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 AbbVie Inc(US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Human Immunodeficiency Virus (HIV)-1 Therapeutics
-
Figure Human Immunodeficiency Virus (HIV)-1 Therapeutics Picture
-
Table Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Country (2017-2022)
-
Figure United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure China Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure India Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Consumption and Growth Rate (2017-2022)
-
Figure Global Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Consumption and Growth Rate (2017-2022)
-
Figure Global Entry and Fusion Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Protease Inhibitors (PIs) Consumption and Growth Rate (2017-2022)
-
Figure Global Integrase Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Coreceptor Antagonists Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Labs Consumption and Growth Rate (2017-2022)
-
Figure Global Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Entry and Fusion Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Protease Inhibitors (PIs) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Integrase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Coreceptor Antagonists Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Labs Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Export by Region (Top 5 Countries) (2017-2028)
-
Table Boehringer Ingelheim GmbH (Germany) (Foundation Year, Company Profile and etc.)
-
Table Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Service
-
Table Bristol-Myers Squibb Company (US) (Foundation Year, Company Profile and etc.)
-
Table Bristol-Myers Squibb Company (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Company (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Service
-
Table Genentech Inc (US) (Foundation Year, Company Profile and etc.)
-
Table Genentech Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genentech Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Service
-
Table Cipla Inc (India) (Foundation Year, Company Profile and etc.)
-
Table Cipla Inc (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cipla Inc (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Service
-
Table Merck & Co Inc (US) (Foundation Year, Company Profile and etc.)
-
Table Merck & Co Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck & Co Inc (US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Service
-
Table AbbVie Inc(US) (Foundation Year, Company Profile and etc.)
-
Table AbbVie Inc(US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table AbbVie Inc(US) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product and Service
-
